İDRAR TAHLİLİYLE ERKEN EVREDE PANKREAS KANSERİ TANISI KONULABİLİNECEK Mİ?
Pankreas kanseri tanı anında yaklaşık %80 oranında ameliyat olma aşamasını geçmiş, metastatik dönemdedir.
Erken tanı konması önemli olmakla beraber günümüze kadar etkili bir tarama tespit edilememiştir.
journal Clinical Cancer Research dergisinin son sayısında çıkan makaleye göre idrarda LYVE1, REG1A ve TFF1proteinlerine bakılarak pankreas kanseri erken evrede tanısı konulabilecek.
Bu üçlü protein testiyle %90 oranında pankreas kanseri erken dönem tanısı konabilinmiş. En önemlisi, kronik pankreatit durumunda bu proteinlerin düzeyinde herhangi bir artış tespit edilmemiş.
Çalışmayı yapan doktor Tatjana Crnogorac-Jurcevic( Barts Cancer Institute, Queen Mary University of London), gelecek 5 yılda bu testin klinikte kullanılmasını öngördüklerini belirtiyor.
Kaynak:Urine Test for Early-Stage Pancreatic Cancer Possible After Biomarker Discovery
August 3, 2015
LONDON — August 3, 2015 — A combination of 3 proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, according to a study published today in the journal Clinical Cancer Research.
The discovery could lead to a non-invasive, inexpensive test to screen people at high risk of developing the disease.
Researcher from the Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, have shown that the 3-protein signature can both identify the most common form of pancreatic cancer when still in its early stages, and distinguish between this cancer and the inflammatory condition chronic pancreatitis, which can be hard to tell apart.
The study looked at 488 urine samples: 192 from patients known to have pancreatic cancer, 92 from patients with chronic pancreatitis, and 87 from healthy volunteers. A further 117 samples from patients with other benign and malignant liver and gall bladder conditions were used for further validation.
Around 1,500 proteins were found in the urine samples, with approximately half being common to both male and female volunteers. Of these, LYVE1, REG1A, and TFF1 were selected for closer examination based on biological information and performance in statistical analysis.
Patients with pancreatic cancer were found to have increased levels of each of the 3 proteins when compared with urine samples from healthy patients, while patients suffering from chronic pancreatitis had significantly lower levels than cancer patients. When combined, the 3 proteins formed a robust panel that can detect patients with stage I or II pancreatic cancer with over 90% accuracy.
With few specific symptoms even at a later stage of the disease, more than 80% of people with pancreatic cancer are diagnosed when the cancer has already spread. This means they are not eligible for surgery to remove the tumour. The 5-year survival rate for pancreatic cancer in the UK is the lowest of any common cancer, standing at 3%. This figure has barely improved in 40 years. There is no early diagnostic test available.
“We’ve always been keen to develop a diagnostic test in urine as it has several advantages over using blood,” said Tatjana Crnogorac-Jurcevic, MD, Barts Cancer Institute. “It’s an inert and far less complex fluid than blood and can be repeatedly and non-invasively tested. It took a while to secure proof of principle funding in 2008 to look at biomarkers in urine, but it’s been worth the wait for these results. This is a biomarker panel with good specificity and sensitivity and we’re hopeful that a simple, inexpensive test can be developed and be in clinical use within the next 5 years.”
SOURCE: Pancreatic Cancer Research Fund